Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T20:01:12.992Z.
Calculation as of: 2026-10-06T20:01:12.992Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8e18e4937bb179ad65bb801f5f057f36d78bd2e4af2c39ec5cecdad017acf428
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BriaCell Therapeutics Corp. (BCTX) | $34.97M | N/A | N/A | N/A | N/A |
| DocGo Inc. (DCGO)vs › | $35.76M | N/A | 8.66x | 44.05x | 43.98x |
| QT Imaging Holdings, Inc. (QTI)vs › | $35.52M | N/A | N/A | N/A | N/A |
| Elicio Therapeutics, Inc. (ELTX)vs › | $35.84M | N/A | N/A | N/A | N/A |
| Elutia Inc (ELUT)vs › | $34.23M | N/A | N/A | N/A | N/A |
| Edesa Biotech, Inc. (EDSA)vs › | $35.84M | N/A | N/A | N/A | N/A |
| Nephros, Inc. (NEPH)vs › | $33.44M | 18.03x | 36.10x | 319.62x | 319.62x |
| Grace Therapeutics, Inc. (GRCE)vs › | $33.61M | N/A | N/A | N/A | N/A |
| Scilex Holding Company (SCLX)vs › | $33.63M | N/A | N/A | N/A | N/A |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.29M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
